Effect of low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) in patients with low-grade cervical squamous intraepithelial lesions (LSIL)

Trial Profile

Effect of low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) in patients with low-grade cervical squamous intraepithelial lesions (LSIL)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs ISA 101 (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 12 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top